Diagnostic Value of MiR-200 Family in Non-small Cell Lung Cancer: a Meta-analysis

Overview

Journal Biomark Med

Specialties Biochemistry
General Medicine

Date 2024 Jul 23

PMID 39041844

Authors

Zhen Ling

Lichang Yang

Affiliations

Soon will be listed here.

Abstract

To investigate the diagnostic potential of the miR-200 family for early detection in non-small cell lung cancer (NSCLC). A systematic search was conducted of PubMed, Embase and Web of Science databases to identify studies of the miR-200 family in NSCLC. Sixteen studies meeting the inclusion criteria were included in the analysis with a total of 20 cohorts. The combined sensitivity and specificity reached 73% and 85%, with an area under the curve of 0.83. Notably, miR-200b introduced heterogeneity. Subgroup analysis highlighted miR-200a and miR-141 as more sensitive, while blood-derived miRNAs showed slightly lower accuracy. The miR-200 family, predominantly assessed in blood, exhibits significant diagnostic potential for NSCLC, especially in distinguishing it from benign diseases.

References

Cavallari I, Ciccarese F, Sharova E, Urso L, Raimondi V, Silic-Benussi M . The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers. Cancers (Basel). 2021; 13(23). PMC: 8656820. DOI: 10.3390/cancers13235874. View

Wu Q, Yu L, Lin X, Zheng Q, Zhang S, Chen D . Combination of Serum miRNAs with Serum Exosomal miRNAs in Early Diagnosis for Non-Small-Cell Lung Cancer. Cancer Manag Res. 2020; 12:485-495. PMC: 6982436. DOI: 10.2147/CMAR.S232383. View

Jiang Z, Yang L, Jin L, Yi L, Bing P, Zhou J . Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients. Front Oncol. 2022; 12:988680. PMC: 9531154. DOI: 10.3389/fonc.2022.988680. View

Halvorsen A, Bjaanaes M, LeBlanc M, Holm A, Bolstad N, Rubio L . A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer. Oncotarget. 2016; 7(24):37250-37259. PMC: 5095073. DOI: 10.18632/oncotarget.9363. View

Liam C, Lee P, Yu C, Bai C, Yasufuku K . The diagnosis of lung cancer in the era of interventional pulmonology. Int J Tuberc Lung Dis. 2021; 25(1):6-15. DOI: 10.5588/ijtld.20.0588. View

Savolainen K, Scaravilli M, Ilvesmaki A, Staff S, Tolonen T, Maenpaa J . Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts. BMC Res Notes. 2020; 13(1):311. PMC: 7329467. DOI: 10.1186/s13104-020-05155-6. View

Salameh J, Bossuyt P, McGrath T, Thombs B, Hyde C, Macaskill P . Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist. BMJ. 2020; 370:m2632. DOI: 10.1136/bmj.m2632. View

Liu C, Hu W, Li L, Wang Y, Zhou Q, Zhang F . Roles of miR-200 family members in lung cancer: more than tumor suppressors. Future Oncol. 2018; 14(27):2875-2886. DOI: 10.2217/fon-2018-0155. View

Amicizia D, Piazza M, Marchini F, Astengo M, Grammatico F, Battaglini A . Systematic Review of Lung Cancer Screening: Advancements and Strategies for Implementation. Healthcare (Basel). 2023; 11(14). PMC: 10379173. DOI: 10.3390/healthcare11142085. View

10.

Dziedzic R, Marjanski T, Rzyman W . A narrative review of invasive diagnostics and treatment of early lung cancer. Transl Lung Cancer Res. 2021; 10(2):1110-1123. PMC: 7947400. DOI: 10.21037/tlcr-20-728. View

11.

Xi K, Wang W, Wen Y, Chen Y, Zhang X, Wu Y . Combining Plasma miRNAs and Computed Tomography Features to Differentiate the Nature of Pulmonary Nodules. Front Oncol. 2019; 9:975. PMC: 6779729. DOI: 10.3389/fonc.2019.00975. View

12.

Huang G, Sun J, Lu Y, Liu Y, Cao H, Zhang H . MiR-200 family and cancer: From a meta-analysis view. Mol Aspects Med. 2019; 70:57-71. DOI: 10.1016/j.mam.2019.09.005. View

13.

Ning J, Ge T, Jiang M, Jia K, Wang L, Li W . Early diagnosis of lung cancer: which is the optimal choice?. Aging (Albany NY). 2021; 13(4):6214-6227. PMC: 7950268. DOI: 10.18632/aging.202504. View

14.

Frydrychowicz M, Kuszel L, Dworacki G, Budna-Tukan J . MicroRNA in lung cancer-a novel potential way for early diagnosis and therapy. J Appl Genet. 2023; 64(3):459-477. PMC: 10457410. DOI: 10.1007/s13353-023-00750-2. View

15.

Arab A, Karimipoor M, Irani S, Kiani A, Zeinali S, Tafsiri E . Potential circulating miRNA signature for early detection of NSCLC. Cancer Genet. 2017; 216-217:150-158. DOI: 10.1016/j.cancergen.2017.07.006. View

16.

Zhu W, He J, Chen D, Zhang B, Xu L, Ma H . Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS One. 2014; 9(2):e87780. PMC: 3921142. DOI: 10.1371/journal.pone.0087780. View

17.

Zhao L, Chen S, Lin L, Sun L, Wu H, Lin Q . [Ga]Ga-DOTA-FAPI-04 improves tumor staging and monitors early response to chemoradiotherapy in a patient with esophageal cancer. Eur J Nucl Med Mol Imaging. 2020; 47(13):3188-3189. DOI: 10.1007/s00259-020-04818-7. View

18.

He Z, Yue C, Chen X, Li X, Zhang L, Tan S . Integrative Analysis Identified CD38 As a Key Node That Correlates Highly with Immunophenotype, Chemoradiotherapy Resistance, And Prognosis of Head and Neck Cancer. J Cancer. 2023; 14(1):72-87. PMC: 9809333. DOI: 10.7150/jca.59730. View

19.

Jiang J, Dong W, Zhang W, Wang Q, Wang R, Wang J . LncRNA Axis Contributes to Malignant Progression of Hepatocellular Carcinoma. Discov Med. 2023; 35(179):995-1014. DOI: 10.24976/Discov.Med.202335179.96. View

20.

Chen X, Liao Y, Long D, Yu T, Shen F, Lin X . The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro. Int J Mol Med. 2017; 40(1):235-242. DOI: 10.3892/ijmm.2017.2989. View